The UN Convention on Biodiversity has rejected a moratorium on gene drives, Nature News says.
The company is hoping to find a niche among customers who want the quality of high-throughput oligonucleotide synthesis but smaller order volumes.
The President's Council of Advisors on Science and Technology urges the adoption of a biodefense strategy, Tech Review reports.
The company said it would use the funding to continue licensing its DNA design technology in the cell and gene therapy markets.
The DNA foundries have been funded through an £18 million ($23.5 million) investment from the BBSRC and should all be fully operational by next year.
In Science this week: effort to reduce E. coli genome, and more.
The Scientist traces the career path of the J. Craig Venter Institute's Clyde Hutchinson.
The firm is developing protein therapies incorporating synthetic amino acids coded for by "unnatural" base pairs developed at The Scripps Research Institute.
The company said it will use the proceeds to fund its growth into new markets, and to build its next-generation automated foundry.
Researchers and business leaders unveil their plan for HGP-write to synthesize full genomes.
In Science this week: metagenomic-based technique for determining protein structure, and more.
An academic laments the rise of narcissism in the sciences, the Guardian reports.
Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.
The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.